Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)

Organization
NCI
Type
NIH
Application Due Date
02-14-2024
Number
PAR-22-256
Comments
LOI due 30 days before application due date
Brief Description

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) intends to accelerate the development of evidence-based cancer-related interventions that reflect the diversity of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.